期刊文献+

S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13)

S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13)
下载PDF
导出
摘要 Adjuvant chemotherapy by S-1 following gastrectomy is considered standard treatment in Japan.Analysis of follow-up data have proved the effi cacy of S-1 admin-istration,and that hematological adverse events were relatively rare.Pyrimidine anti-metabolites,including S-1,have shown relatively lower risks for secondary hematological malignancies in comparison to alkylat-ing agents and topoisomerase-Ⅱ inhibitors.We here report a case of therapy-related leukemia after S-1 administration.A patient who had received S-1as the sole adjuvant chemotherapy was diagnosed with acute erythroid leukemia.To the best of our knowledge,our patient represents the fi rst report of S-1 induced acute leukemia. Adjuvant chemotherapy by S-1 following gastrectomy is considered standard treatment in Japan.Analysis of follow-up data have proved the effi cacy of S-1 admin-istration,and that hematological adverse events were relatively rare.Pyrimidine anti-metabolites,including S-1,have shown relatively lower risks for secondary hematological malignancies in comparison to alkylat-ing agents and topoisomerase-Ⅱ inhibitors.We here report a case of therapy-related leukemia after S-1 administration.A patient who had received S-1as the sole adjuvant chemotherapy was diagnosed with acute erythroid leukemia.To the best of our knowledge,our patient represents the fi rst report of S-1 induced acute leukemia.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第41期4632-4634,共3页 世界胃肠病学杂志(英文版)
关键词 S-1 Secondary leukemia Acute erythroidLeukemia Gastric cancer 急性白血病 红白血病 S-1 染色体 继发性 诱导 恶性血液病 拓扑异构酶
  • 相关文献

参考文献1

二级参考文献22

  • 1Munoz N,Franceschi S.Epidemiology of gastric cancer and perspectives for prevention.Salud Publica Mex 1997;39:318-330.
  • 2Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol 2006;24:2137-2150.
  • 3Glimelius B,Ekstrom K,Hoffman K,Graf W,Sjodén PO,Haglund U,Svensson C,Enander LK,Linné T,Sellstrom H,Heuman R.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol 1997;8:163-168.
  • 4Webb A,Cunningham D,Scarffe JH,Harper P,Norman A,Joffe JK,Hughes M,Mansi J,Findlay M,Hill A,Oates J,Nicolson M,Hickish T,O'Brien M,Iveson T,Watson M,Underhill C,Wardley A,Meehan M.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer.J Clin Oncol 1997;15:261-267.
  • 5Wagner AD,Grothe W,Haerting J,Kleber G,Grothey A,Fleig WE.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data.J Clin Oncol 2006;24:2903-2909.
  • 6Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997.
  • 7Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2008;358:36-46.
  • 8Kang Y,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Salas MP,Suarez T,Santamaria J.Randomized phase III trial of capecitabine/cisplatin (XP) vs.continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):efficacy and safety results.Proceedings of the 42nd Annual Meeting of American Society of Clinical Oncology;2006 June 1-5;Chicago,USA.Alexandria:American Society of Clinical Oncology,2006:18s.
  • 9Koizumi W,Narahara H,Hara T,Takagane A,Akiya T,Takagi M,Miyashita K,Nishizaki T,Kobayashi O,Takiyama W,Toh Y,Nagaie T,Takagi S,Yamamura Y,Yanaoka K,Orita H,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial.Lancet Oncol 2008;9:215-221.
  • 10Ajani JA,Rodriguez W,Bodoky G,Moiseyenko V,Lichinitser M,Gorbunova V,Vynnychenko I,Garin A,Lang I,Falcon S.Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS).Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium;2009 January 15-17;San Francisco,USA.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部